The research will focus on data originating from biotechnology companies,academia and from internal research projects.
The studies will be carried out from Type 1 Diabetes R&D Center of Novo Nordisk in Seattle, US.
The Center’s primary aim will be to use translational research methods and move new discovery projects in immunotherapy from animal models to small clinical exploratory trials in T1D.
JDRF chief scientific officer Dr Richard Insel said, "JDRF is deeply committed to developing immunotherapies and especially auto antigen-specific immunotherapies for prevention and cure of type 1 diabetes."
Novo Nordisk executive vice president and chief science officer Mads Krogsgaard Thomsen said, "It is not a coincidence that we are opening our new Type 1 Diabetes Research and Development Center in Seattle at that same time that we announce a scientific partnership between our company and the JDRF.”